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The Concurrent Accumulation of Intra-Abdominal and
Subcutaneous Fat Explains the Association Between
Insulin Resistance and Plasma Leptin Concentrations
Distinct Metabolic Effects of Two Fat Compartments
Miriam Cnop,1 Melinda J. Landchild,1 Josep Vidal,1 Peter J. Havel,3 Negar G. Knowles,1
Darcy R. Carr,2 Feng Wang,1 Rebecca L. Hull,1 Edward J. Boyko,1 Barbara M. Retzlaff,1
Carolyn E. Walden,4 Robert H. Knopp,1 and Steven E. Kahn1
Obesity is associated with insulin resistance, particu-
larly when body fat has a central distribution. However,
insulin resistance also frequently occurs in apparently
lean individuals. It has been proposed that these lean
insulin-resistant individuals have greater amounts of
body fat than lean insulin-sensitive subjects. Alterna-
tively, their body fat distribution may be different.
Obesity is associated with elevated plasma leptin levels,
but some studies have suggested that insulin sensitivity
is an additional determinant of circulating leptin con-
centrations. To examine how body fat distribution con-
tributes to insulin sensitivity and how these variables
are related to leptin levels, we studied 174 individuals
(73 men, 101 women), a priori classified as lean insulin-
sensitive (LIS, n  56), lean insulin-resistant (LIR, n 
61), and obese insulin-resistant (OIR, n  57) based on
their BMI and insulin sensitivity index (SI). Whereas
the BMI of the two lean groups did not differ, the SI of
the LIR subjects was less than half that of the LIS group.
The subcutaneous and intra-abdominal fat areas, deter-
mined by computed tomography, were 45 and 70%
greater in the LIR subjects (P < 0.001) and 2.5- and
3-fold greater in the OIR group, as compared with the
LIS group. Fasting plasma leptin levels were moderately
increased in LIR subjects (10.8  7.1 vs. 8.1  6.4 ng/ml
in LIS subjects; P < 0.001) and doubled in OIR subjects
(21.9 15.5 ng/ml; P < 0.001). Because of the confound-
ing effect of body fat, we examined the relationships
between adiposity, insulin sensitivity, and leptin con-
centrations by multiple regression analysis. Intra-
abdominal fat was the best variable predicting insulin
sensitivity in both genders and explained 54% of the
variance in SI. This inverse relationship was nonlinear
(r  0.688). On the other hand, in both genders,
fasting leptin levels were strongly associated with sub-
cutaneous fat area (r  0.760) but not with intra-
abdominal fat. In line with these analyses, when LIS and
LIR subjects were matched for subcutaneous fat area,
age, and gender, they had similar leptin levels, whereas
their intra-abdominal fat and insulin sensitivity re-
mained different. Thus, accumulation of intra-abdomi-
nal fat correlates with insulin resistance, whereas
subcutaneous fat deposition correlates with circulating
leptin levels. We conclude that the concurrent increase
in these two metabolically distinct fat compartments is
a major explanation for the association between insulin
resistance and elevated circulating leptin concentra-
tions in lean and obese subjects. Diabetes 51:
1005–1015, 2002
The role of insulin resistance in metabolic dis-eases has received considerable attention inrecent years (1). Insulin resistance has beensuggested to be an important risk factor in the
development of the metabolic syndrome, a cluster of
disorders comprising glucose intolerance, dyslipidemia,
hypertension, and dysfibrinolysis that is associated with
type 2 diabetes and cardiovascular disease (2). It is evident
that obesity is a risk factor for these same conditions and
that this association is not only related to the degree of
obesity, but also appears to be critically dependent on
body fat distribution. Thus, individuals with greater de-
grees of central adiposity appear to develop this syndrome
more frequently than those with a peripheral body fat
distribution (3,4).
Although the metabolic impact of central versus periph-
eral body fat has been firmly established, the importance
of the site of abdominal fat accumulation in relation to
insulin sensitivity is still a matter of some debate. In recent
years, imaging techniques have become available to quan-
tify abdominal fat localized within or outside of the
peritoneum. Although there now seems to be a consensus
that these two fat compartments are metabolically quite
different, studies have differed in the assessment of their
relative importance. Some studies have suggested that the
intra-abdominal fat (IAF) depot is the major determinant
of insulin resistance (5–7) and of other features of the
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metabolic syndrome (8,9), whereas others have suggested
that the subcutaneous fat (SCF) compartment is the most
critical determinant of insulin sensitivity (10,11). Most of
these studies evaluated relatively small numbers of sub-
jects and frequently compared subjects who were differ-
ent, being either lean and insulin sensitive or (very) obese
and insulin resistant.
Insulin resistance also frequently occurs in apparently
lean individuals (12–14). Because these lean insulin-resis-
tant subjects have had a slightly greater BMI (12) or
calculated fat mass (14), it has been suggested that they
may be more obese than lean insulin-sensitive individuals
(15). However, detailed studies examining abdominal fat
distribution and its relationship to insulin sensitivity in
these subjects are lacking.
Body adiposity has been shown to be a major determi-
nant of circulating leptin (16), an adipocyte-derived hor-
mone involved in body weight regulation. Whereas women
have higher leptin concentrations, even after correction
for body fat mass (17), in both genders the SCF depot
seems to be a stronger predictor of leptin levels than IAF
(18). Insulin sensitivity has been suggested to be an
additional determinant of leptin concentrations (19), pos-
sibly through stimulation of leptin secretion from adipose
cells by insulin (19,20). However, the association between
insulin and leptin is difficult to evaluate because of the
ability of adiposity to influence both leptin levels and
insulin sensitivity. The relative contribution of different fat
compartments, insulin sensitivity, and insulin levels on
fasting leptin concentrations has not yet been examined in
a large number of male and female subjects with a broad
spectrum of insulin sensitivity and body size.
To systematically examine the relationships between
body fat distribution, insulin sensitivity, and leptin concen-
trations, we quantified these variables in apparently
healthy individuals who were classified a priori into three
groups: lean insulin-sensitive (LIS), lean insulin-resistant
(LIR), and obese insulin-resistant (OIR). By design, the
lean groups would differ in insulin sensitivity, while the
LIR and OIR would have a different BMI. All subjects
underwent computed tomography (CT) scanning of the
abdomen to quantify intra-abdominal and SCF depots. Our
aims were 1) to examine the relative effects of insulin
sensitivity and obesity on plasma leptin levels, 2) to assess
the role of IAF versus SCF distribution on insulin sensi-
tivity and plasma leptin levels, and 3) to examine the
possible effect of gender on these relationships.
RESEARCH DESIGN AND METHODS
Subjects. A total of 234 (99 men, 135 women) individuals were recruited by
advertisement to participate in a study of the effect of egg consumption on
plasma lipids in people with varying degrees of insulin sensitivity. This study
was reviewed and approved by the Human Subjects Review Committee at the
University of Washington. The data presented in this article are baseline
measurements in 174 subjects (73 men, 101 women), for whom data on insulin
sensitivity, body fat distribution, and plasma leptin concentrations were
available.
The subjects, aged 30–75 years, were apparently healthy, with no history of
diabetes, dyslipidemia, or uncontrolled hypertension. Further exclusion cri-
teria were fasting plasma glucose 6.4 mmol/l, biochemical evidence of liver
or renal disease, uncontrolled thyroid disease, coronary or other vascular
disease, and anemia. Premenopausal women (n  40) were not studied in any
particular phase of the menstrual cycle. Of the postmenopausal women, 34%
were not using hormone replacement therapy, 28% were taking estrogen, and
38% were taking estrogen and progestin.
Eligible subjects had their height and weight measured and underwent a
frequently sampled intravenous glucose tolerance test (FSIGT) to quantify
insulin sensitivity. Based on their BMI and insulin sensitivity, subjects were a
priori subdivided into three groups: LIS, LIR, and OIR, as discussed above. Ten
obese insulin-sensitive subjects were excluded from the study because of their
small number. The cutoff points used were 27.5 kg/m2 for BMI, based on the
criteria used before the redefinition of overweight and obesity (National
Health and Nutrition Examination Survey [NHANES] II), and 7  105 min1
 [pmol/l]1 for the insulin sensitivity index (SI), which represented the highest
value for this parameter among a group of apparently healthy obese subjects
studied in Seattle (13). After their subdivision into LIS, LIR and OIR groups,
subjects underwent additional measures of body anthropometry and body fat
distribution. The ethnicity of subjects was Caucasian in 96% of the LIS and 89%
of the LIR and OIR groups and Asian American in 3%. In addition, in the LIR
and OIR groups, 6% were African-American and 2% were Hispanic or Native
American.
Study procedures
Measures of anthropometry and body fat distribution. The average of
two weight and height measurements were used to calculate BMI as weight
(kg)/[height (m)]2.
Waist and hip circumferences were calculated as the average of two
measurements. Waist circumference was measured at the smallest circumfer-
ence of the waist, and hip circumference was measured at the widest level of
the buttocks, using a protocol described in the NHANES III Anthropometric
Measurements Videotape (National Center for Health Statistics).
A CT scan of the abdomen was performed at the level of the umbilicus to
quantify SCF area, IAF area, and total tissue area. Total tissue area was
computed as the area with an attenuation range of 250 to 1,500 Hounsfield
units, whereas for fat, an attenuation range of 250 to 50 Hounsfield units
was used. IAF and SCF areas were quantified by delineating the border of the
peritoneal cavity. These measurements were performed by a single observer
using standard GE 8800 computer software. The variability of these measures
made by a single observer was 1.5%, and day-to-day variability was 1% (21).
Insulin sensitivity. Subjects underwent a tolbutamide-modified FSIGT to
quantify insulin sensitivity as the SI using Bergman’s minimal model of glucose
kinetics (22). During this test, three basal blood samples were drawn at 15,
5, and 1 min before intravenous glucose administration at time 0. Glucose
(11.4 g/m2 body surface area) was infused over 1 min, and blood sampling was
continued at 2, 3, 4, 5, 6, 8, 10, 14, 16, and 19 min after commencement of
glucose administration. At time 20 min, tolbutamide (125 mg/m2 body surface
area) was administered over 30 s, and blood sampling was continued at 22, 23,
24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, and 240
min. Fasting glucose and immunoreactive insulin concentrations were calcu-
lated as the average of the three basal samples. In our laboratory, the
day-to-day variability of SI was 16.9% (23). The fasting plasma leptin concen-
tration was determined on a basal sample obtained at the time of the FSIGT.
Assays. Glucose was measured in duplicate using the glucose oxidase
method. Immunoreactive insulin was measured in duplicate by radioimmuno-
assay using a modification of the double antibody technique (24). Plasma
leptin levels were measured by radioimmunoassay (25) (Linco Research, St.
Charles, MO). Samples from subjects in each of the three different study
groups were included in each assay to reduce the effect of interassay
variability.
Calculations and statistics. Data are presented as means  SD. Compari-
sons of LIS, LIR, and OIR groups and comparisons between genders were
performed by ANOVA. There was no interaction between group and gender
effect for any of the variables by two-way ANOVA. Neither was an interaction
observed between group and menopausal status. This result suggests that the
differences across LIS, LIR, and OIR groups were not affected by gender or
menopausal status. Subsequently, we used one-way ANOVA followed by
Bonferroni’s post test to compare groups and to test for differences between
genders within each group. SI, fasting plasma insulin and leptin levels, and
SCF and IAF areas were not normally distributed and were therefore
log-transformed before ANOVA.
Scatterplots were made to visually evaluate the relationships between
continuous variables in the group of 174 subjects. Correlations were per-
formed by linear regression. These analyses were repeated after inclusion of
the obese insulin-sensitive subjects (n  10), who were previously excluded
by study design. The results obtained when this group of subjects was
included in the analyses were not different. For the assessment of the
relationship between insulin sensitivity and measures of body fat, variables
were log-transformed because the relationship between untransformed vari-
ables appeared nonlinear. To test whether the association between IAF and SI
is indeed best described by a nonlinear function, we inserted natural log (loge)
IAF in a multiple regression model that already contained IAF as a linear
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independent variable. This nonlinear regression model was compared with the
linear model for prediction of loge SI using a partial F test.
The relative contribution of fat compartments on insulin sensitivity and
leptin levels was examined by subanalysis of LIS and LIR subjects and of LIR
and OIR subjects. The subjects were matched for gender and SCF or IAF area
by pairwise selection of individuals with fat areas differing 10 cm2. The
subgroups were then compared by unpaired t test and by Mann-Whitney U test
for non–normally distributed variables.
Multiple regression analysis was used to determine whether the associa-
tion between the dependent and independent variables of interest remained
significant after adjusting for other potentially confounding independent
variables. In this analysis, the dependent variables were log-transformed to
satisfy the necessary statistical assumptions of linear regression. Stepwise
model building was used to estimate the relative contribution of the indepen-
dent variables to the variability of the dependent variable. The multiple
regression analyses were repeated after inclusion in the cohort of the obese
FIG. 1. BMI (A), SI (B), total abdominal fat area (C), SCF area (D), IAF area (E), and fasting plasma leptin levels (F) in 56 LIS (), 61 LIR (u),
and 57 OIR (f) subjects. *P < 0.001 vs. LIS; ∧P < 0.001 vs. LIR. SI, fat areas, and leptin levels were log-transformed before ANOVA because they
were not normally distributed.
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insulin-sensitive subjects (n  10), who were previously excluded by study
design. The results obtained when these subjects were included in the
analyses were not different. A P value 0.05 was considered significant.
RESULTS
Demographic, adiposity, and metabolic characteris-
tics. In this apparently healthy group of subjects, 68%
were insulin resistant (defined as SI 7  10
5 min1 
[pmol/l]1) and 33% were obese (defined as BMI 27.5
kg/m2). The mean age of the insulin-sensitive subjects was
49.5  8.3 years, slightly less than that of the LIR and OIR
subjects (54.2 11.5 and 53.6 9.7 years; P 0.05, LIR vs.
LIS). Conforming to the a priori classification of the
subjects, the BMI of the obese group (31.0  3.4) was
higher than that of both lean groups (LIS 23.4  2.3 and
LIR 24.2 1.7; Fig. 1A) as a result of a20 kg higher mean
weight in the obese subjects (P  0.001) for a similar
height. On the other hand, the BMI of the lean groups did
not differ. By definition, the SI of the insulin-sensitive
subjects was more than two- and threefold greater than
that of the LIR and OIR subjects, respectively (Fig. 1B). SI
was only 40% greater in the LIR group compared with the
OIR group. The differences in age, BMI, and SI between the
LIS, LIR, and OIR groups were similar when men and
women were analyzed separately (Table 1).
As expected, the insulin-resistant subjects were rela-
tively hyperinsulinemic. Fasting insulin concentrations
were twofold higher in the OIR subjects (91.2  58.8
pmol/l) compared with the insulin-sensitive group (41.4 
17.4 pmol/l; P  0.001), with an intermediate level in the
LIR group (60.0  27.6 pmol/l; P  0.001 vs. OIR and LIS).
Similarly, the mean fasting glucose concentration was
higher in the LIR group than in the LIS group (5.42  0.39
vs. 5.22 0.37 mmol/l; P 0.01) and was further increased
in the OIR group (5.63  0.49 mmol/l; P  0.01 vs. LIR and
P  0.001 vs. LIS).
The waist-to-hip ratio was 0.78 0.08 in the LIS subjects
and increased to 0.83  0.09 in the LIR group (P  0.001
vs. LIS) and to 0.89  0.08 in the OIR group (P  0.001 vs.
both), suggestive of a more central body fat distribution in
the insulin-resistant groups. In the LIR subjects, the in-
creased ratio resulted from a greater waist circumference
(83.2  9.1 vs. 77.7  8.5 cm for LIS; P  0.01) for an
unchanged hip circumference (100.9  4.9 vs. 99.3  6.3
cm). As expected, women had markedly lower waist-to-hip
ratios than men in all groups (Table 2).
In line with the waist circumference data, insulin-
resistant subjects had greater amounts of abdominal fat
measured by a CT scan (LIR 275  93 cm2 vs. LIS 181 
71 cm2; P  0.001; Fig. 1C). For similar BMI values, the
LIR subjects had 45% more abdominal SCF than the LIS
group (LIR 189  71 cm2 vs. LIS 132  59 cm2; P  0.001;
Fig. 1D). Their IAF area was also increased by 70% (LIR
85  41 cm2 vs. LIS 50  27 cm2; P  0.001; Fig. 1E).
This overall 50% increase in abdominal fat was present
in both sexes, but women had less IAF and more SCF
than men (Table 2). In the LIR group, postmenopausal
women had more IAF than premenopausal women (P 
0.05), but, as mentioned in RESEARCH DESIGN AND METHODS,
the differences between the LIS, LIR, and OIR groups
were not affected by menopausal status. The increase in
abdominal fat was even greater in the obese subjects. As
compared with the LIS group, they had 2.5- and 3-fold
greater SCF (318  127 cm2; P  0.001 vs. LIS and LIR)
and IAF areas (159  64 cm2; P  0.001 vs. LIS and LIR),
respectively (Fig. 1D and E). The total area of the
abdomen, including all tissues, was also larger in the
insulin-resistant groups and more so in the obese sub-
jects. However, this was fully accounted for by the
increase in abdominal fat because the nonadipose tissue
areas did not differ between the LIS, LIR, and OIR
groups (297  56, 295  52, and 315  61 cm2,
respectively).
The increased fat area in the obese subjects was associ-
ated with a threefold elevation in their fasting leptin concen-
tration (21.9 15.5 vs. 8.1 6.4 ng/ml for LIS and 10.8 7.1
ng/ml for LIR; all comparisons P  0.001; Fig. 1F). This
TABLE 1
Age, BMI, and metabolic characteristics of LIS, LIR, and OIR
subjects subdivided by gender
LIS LIR OIR
Men
n 19 27 27
Age (years) 46.6 7.3 55.7 11.5† 53.9 10.1
BMI (kg/m2) 24.1 2.3 24.8  1.4 30.5 2.7‡¶
SI ( 10
5 min1
 [pmol/l]1) 11.3 5.2 4.3 0.5‡ 3.3 1.3‡
Glucose (mmol/l) 5.36 0.42 5.59 0.39 5.77 0.47†
Insulin (pmol/l) 45.0 19.2 63.6 25.2* 88.2 69.6‡
Women
n 37 34 30
Age (years) 51.0 8.6 53.0  11.5 53.3 9.5
BMI (kg/m2) 23.0 2.2 23.8  1.8# 31.5 3.9‡¶
SI ( 10
5 min1
 [pmol/l]1) 10.7 3.7 5.2 1.2‡# 3.7  1.7‡¶
Glucose (mmol/l) 5.14 0.33# 5.28 0.33** 5.52 0.48‡§
Insulin (pmol/l) 39.6 16.2 57.0 29.4† 93.6 48.6‡¶
Data are means  SD. *P  0.05, †P  0.01, ‡P  0.001 vs. LIS; §P 
0.05, P  0.01, ¶P  0.001 vs. LIR; #P  0.05, **P  0.01 for women
vs. men within the group. SI and insulin were log-transformed to
obtain normal distribution of the variable before ANOVA.
TABLE 2
Body fat distribution and fasting plasma leptin concentrations in
LIS, LIR, and OIR subjects subdivided by gender
LIS LIR OIR
Men
n 19 27 27
Waist-to-hip ratio 0.87 0.06 0.90 0.05 0.96 0.05†‡
Total fat area
(cm2) 175 64 264 85† 431 100†‡
SCF area (cm2) 110 51 166 64† 248 87†‡
IAF area (cm2) 65  28 98  38* 183 62†‡
Leptin (ng/ml) 3.1 1.0 6.0 3.9† 10.1 6.2†‡
Women
n 37 34 30
Waist-to-hip ratio 0.75 0.06¶ 0.77 0.05¶ 0.83 0.05†‡¶
Total fat area
(cm2) 185 75 283 99† 517 160†‡§
SCF area (cm2) 143 61 208 72†§ 381 124†‡¶
IAF area (cm2) 42  23 75  42†§ 136 59†‡¶
Leptin (ng/ml) 10.7 6.6¶ 14.6 6.8*¶ 32.5 13.6†‡¶
Data are means  SD. *P  0.01, †P  0.001 vs. LIS; ‡P  0.001 vs.
LIR; §P  0.05, P  0.01, ¶P  0.001 for women vs. men within the
group. Fat areas and leptin levels were log-transformed to obtain
normal distribution of the variable before ANOVA.
M. CNOP AND ASSOCIATES
1008 DIABETES, VOL. 51, APRIL 2002
increase in leptin levels occurred in both men and women
(Table 2). Women had about threefold higher leptin levels
than men, a gender difference that was present in all three
groups (Table 2). Leptin levels were also elevated in LIR
subjects compared with the LIS group, doubling in men, and
increased by one-third in women (Table 2).
Relationship between body adiposity, fat distribu-
tion, and insulin sensitivity. In this cohort of 174
subjects, insulin sensitivity was inversely correlated with
measures of body fat (Fig. 2). After loge transformation of
variables that were not normally distributed, the correla-
tion coefficient for SI and BMI was 0.634 (P  0.001; Fig.
FIG. 2. Relationships between the SI and BMI (A) and measures of body fat distribution:waist-to-hip ratio (C), SCF area (E), and IAF area (G)
in 174 subjects classified as LIS (f), LIR (‚), or OIR (F). B, D, F, and H display the correlations between SI and adiposity measures after loge
transformation of non–normally distributed variables. P < 0.001 for all correlations.
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2B), 0.498 for waist-to-hip ratio (P  0.001; Fig. 2D),
0.570 for SCF (P  0.001; Fig. 2F), and 0.688 for IAF
(P  0.001; Fig. 2H). These correlations were similar in
both genders and in pre- and postmenopausal women. As
shown in Fig. 2G, the relationship between the untrans-
formed variables SI and IAF area appeared to be nonlinear.
Comparison of two regression models, containing either
IAF alone (linear) or IAF and loge IAF (nonlinear), indi-
cated that the relationship was indeed better described by
the nonlinear model (P  0.02). Because of this nonlinear-
ity, progressive but similar increments in the amount of
IAF are associated with smaller decrements in insulin
sensitivity. Despite a 6.8 kg/m2 mean difference in BMI
between the LIR and OIR subjects, there was a significant
overlap in their IAF areas (Fig. 2G).
We further examined the contribution of IAF to SI by
individually matching two subgroups of LIR and OIR
subjects (n  27 per group) for gender (11 men and 16
women in each group) and IAF area (LIR 117  35 cm2
vs. OIR 120  32 cm2). Their SI was not different (LIR
4.6  1.5  105 min1  [pmol/l]1 vs. OIR 4.0  1.4 
105 min1  [pmol/l]1), although BMI (24.6  1.4 vs.
30.0  2.4 kg/m2; P  0.001), SCF area (213  71 vs.
304  94 cm2; P  0.001), and leptin levels (12.5  7.5 vs.
20.4  14.5 ng/ml; P  0.05) were still higher in the
obese individuals.
By multiple regression analysis, we analyzed the as-
sociations between measures of body fat distribution
and insulin sensitivity simultaneously. In all subjects, SI
was highly inversely correlated with IAF (P  0.001) but
not with SCF, BMI, or waist-to-hip ratio (Table 3). In this
model, 54% of the variance in SI could be accounted for
by IAF area. Using stepwise model building, an addi-
tional 5% of the variance in SI could be attributed to SCF.
Similarly, when the analysis was run in men and women
separately, SI was strongly predicted by IAF (regression
coefficient 0.004  0.001; P  0.003 in both genders)
and not by any other variable, explaining 51 and 57% of
its variability, respectively. In the regression model, IAF
was the only variable that predicted SI in subgroup
analyses of pre- and postmenopausal women. When only
lean subjects were included in the multiple regression
analysis, SI was predicted by IAF (regression coefficient
0.007  0.001; P  0.001) but not by age, sex,
waist-to-hip ratio, or SCF.
Relationship between body adiposity, fat distribu-
tion, and leptin levels. First, we examined the relation-
ships between leptin concentrations and measures of
body fat distribution using simple linear regression in all
subjects. A strong correlation was observed with BMI
(r  0.555; P  0.001) and SCF (r  0.760; P  0.001) and
IAF (r  0.301; P  0.001) areas. Thus, leptin levels were
most strongly correlated with SCF area. Interestingly,
the correlation coefficient for total abdominal fat area
(r  0.679) was not greater than that for SCF area alone.
When genders were analyzed separately (Fig. 3), the
correlation coefficients for leptin were greatest with SCF
in both men and women (r  0.754 for men, r  0.783 for
women; P  0.001 for both; Fig. 3F). Similar correlation
coefficients were observed for pre- and postmenopausal
women.
Second, we examined the relationship between insulin
sensitivity and leptin concentrations. Although their BMI
was not different, the LIR group had leptin levels 33%
higher than the LIS group (Fig. 1F). An increase in leptin
levels was seen in both male and female LIR subjects, by 94
and 36%, respectively (P  0.01, Table 2). However, be-
cause of the 50% greater abdominal fat area in insulin-
resistant subjects, it was not possible to discern whether
this hyperleptinemia was associated primarily with insulin
resistance or with abdominal adiposity.
To examine whether the higher leptin levels in the LIR
group were associated with increased adiposity or re-
duced insulin sensitivity, we examined whether leptin
levels were different in two subgroups of 38 LIS and 38
LIR subjects with comparable SCF areas. As shown in
Table 4, by definition, the LIR group still had a lower SI.
Age and BMI were not different, and the two groups were
well matched for SCF area (Table 4). In contrast, the LIR
subjects still had a 30% greater IAF area (P  0.05). They
were hyperinsulinemic, but their leptin levels were
similar to those of LIS subjects matched for SCF area
(Table 4). In contrast, in a subgroup of LIR subjects (n 
37; 15 men and 22 women) matched with LIS subjects for
age, sex, BMI, and IAF area (LIR 62  27 cm2 vs.
LIS 61  26 cm2), SCF area was significantly greater
(174  74 cm2 vs. LIS 139  57 cm2; P  0.05), as were
leptin levels (11.1  7.4 ng/ml vs. LIS 7.9  6.0 ng/ml;
P  0.05).
We performed multiple regression analysis using step-
TABLE 3
Multiple linear regression analysis of the relationship between
insulin sensitivity and age, gender, and measures of body fat
distribution
Independent
variables Coefficient SE P
Age 0.002 0.004 0.67
Gender 0.002 0.129 0.99
BMI 0.021 0.016 0.19
Waist-to-hip ratio 0.627 0.790 0.43
SCF area 0.001 0.001 0.06
IAF area 0.004 0.001 0.001
Intercept 2.956 0.702 0.001
The dependent variable is loge SI. The model r
2 is 0.544. Sex was
coded (0, 1) with the higher number indicating female sex. SE is the
standard error for the regression coefficient.
TABLE 4
Body fat distribution and fasting plasma leptin concentrations in
a subgroup of LIS and LIR subjects matched for SCF area and
gender (14 men/24 women)
LIS LIR
n 38 38
Age (years) 49.6 8.5 53.2 12.0
BMI (kg/m2) 24.1 1.7 23.6  1.7
SI ( 10
5 min1  [pmol/l]1) 10.5 3.8 5.2  1.3*
SCF area (cm2) 157  52 160  52
Waist-to-hip ratio 0.79 0.08 0.80 0.09
IAF area (cm2) 56  29 73  39†
Insulin (pmol/l) 42.6 19.2 53.4  24.6†
Leptin (ng/ml) 8.8 7.1 9.2  5.9
Data are means  SD. *P  0.001; †P  0.05.
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wise model building to analyze the association between
leptin levels, body fat distribution, and insulin sensitivity
simultaneously. As shown in Table 5, the strongest asso-
ciation was seen with SCF area in both sexes. By stepwise
regression analysis of the same variables, SCF area ac-
counted for 66% of the variance in leptin levels in men and
54% in women. The effect of other variables was minimal.
In the stepwise regression model, 6% of the variance of
leptin levels in men could be explained by IAF area and 2%
by fasting insulin levels. In women, 4% was accounted for
by SI. In women, but not in men, age was negatively
associated with leptin levels.
FIG. 3. Relationships between fasting plasma leptin levels and measures of body fat distribution in 174 subjects classified as LIS (f), LIR (‚),
or OIR (F). Correlation coefficients were determined for men (}) and women (). P < 0.001 for all correlations.
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DISCUSSION
We examined the relationship between body fat distribu-
tion, insulin sensitivity, and leptin concentrations in 174
apparently healthy individuals (73 men and 101 women).
Based on their BMI and SI, they were a priori classified as
either LIS, LIR, or OIR. Although the BMI of the LIR
subjects was similar to that of the LIS group, they had a
more central body fat distribution. Waist circumference
was greater, and this was attributable to a 50% increase in
abdominal fat area, whereas nonfat tissue area was not
different. However, the increase in waist-to-hip ratio be-
tween the LIS and LIR groups was small (0.02 for both
genders). Among the measures of body fat distribution,
IAF area was best correlated with SI, and this was true for
men and women and for pre- and postmenopausal women.
This relatively small fat compartment [comprising 30% of
abdominal and 10–20% of total body fat (10,26)] explained
54% of the variance of SI.
Our finding that IAF is the major predictor of insulin
sensitivity is in agreement with previous studies in 9 (6)
and 16 men (26), in 25 black and white obese women (5),
and in 55 postmenopausal women (7). It has been pro-
posed that IAF is only associated with insulin resistance in
the setting of obesity because indexes of glucose intoler-
ance and dyslipidemia correlated with IAF in obese sub-
jects but not in lean subjects (27). Bonora et al. (28) found
that, in nonobese women, IAF is not correlated with
glucose disposal after correction for total body fat,
whereas in obese women, fat distribution rather than total
fat mass assumes a critical role. Our data do not support
this proposition and are in agreement with others (29,30)
in that central abdominal fat distribution is a good predic-
tor of insulin sensitivity in lean individuals. Although total
body fat was not measured in our study, adjustment for
BMI, as a measure of overall obesity, did not weaken the
correlation between IAF and SI in lean subjects. In addi-
tion, we have shown that this relationship is nonlinear.
Thus, small increases in IAF area are associated with
larger reductions in insulin sensitivity when small amounts
of IAF are present, whereas the effect quantitatively dimin-
ishes as IAF accumulates.
Abate et al. (10) suggested that SCF is the major
determinant of insulin sensitivity in obese men, whereas
intra- and retroperitoneal fat have a lesser role (10).
They also studied type 2 diabetic patients and found that
they were more insulin resistant and had more SCF but
similar IAF than nondiabetic control subjects. Goodpas-
ter et al. (11) found that total abdominal fat was strongly
correlated with the insulin-stimulated glucose disposal
rate but that IAF was not as good a predictor of insulin
sensitivity as SCF in obese subjects, whereas in lean
subjects, no correlations were detected. In contrast, an
interventional study of diet-induced weight loss, by the
same group, showed that the improvement in insulin
sensitivity correlated with the decrease in IAF but not
with other measures of body composition (31). The
apparent contradiction between these reports may pos-
sibly be explained by the nonlinearity of the IAF/insulin
sensitivity relationship [apparent in the study by Good-
paster et al. (11) and also in a rodent model of visceral
fat accumulation and insulin resistance (32)]. Indeed, it
is conceivable that a linear regression model using
nontransformed variables, as in the study by Goodpas-
ter et al., failed to detect the strength of this relation-
ship. Our approach to examine the relationship between
SI and measures of body fat distribution using a nonlin-
ear regression model clearly demonstrates that IAF is the
critical variable predicting insulin sensitivity.
The mechanism(s) by which IAF causes insulin resis-
tance is not clear. It has been suggested that elevated
free fatty acid concentrations are involved in the asso-
ciation between IAF and insulin resistance. Intra-ab-
dominal fat is relatively insensitive to insulin (26,33)
and has a high lipolytic activity (26,34). In addition,
subcutaneous adipocytes from women with visceral
obesity exhibit higher lipolysis rates than those ob-
tained from women with little visceral fat (35). The
increased plasma free fatty acid concentrations associ-
ated with intra-abdominal adiposity may induce fat
accumulation and insulin insensitivity in skeletal muscle
(36,37) and liver (38,39). It remains to be determined
whether enlargement of the IAF depot is causally re-
lated to the triglyceride accumulation in liver and
muscle or whether it is a marker of the process of fat
deposition in these and other nonadipose tissues. Other
adipocyte-derived proteins may also play a role in the
pathogenesis of insulin resistance. For instance, tumor
necrosis factor- impairs insulin receptor signaling in
an autocrine or paracrine form (40); its expression in
SCF has been shown to correlate with IAF mass in
rodents (41), and some studies have suggested that
circulating tumor necrosis factor- levels correlate with
TABLE 5
Multiple regression analysis of the association between fasting plasma leptin levels and measures of body fat distribution and
insulin sensitivity
Independent variables
Men Women
Coefficient SE P Coefficient SE P
Age 0.005 0.005 0.31 0.012 0.005 0.03
BMI 0.020 0.021 0.33 0.010 0.021 0.64
Waist-to-hip ratio 0.788 1.033 0.45 0.806 1.035 0.44
SCF area 0.005 0.001 0.001 0.002 0.001 0.002
IAF area 0.002 0.001 0.046 0.003 0.002 0.07
SI 0.030 0.020 0.14 0.062 0.025 0.02
Insulin 0.015 0.006 0.02 1  105 0.011 1.0
Intercept 1.460 0.932 0.12 3.118 0.812 0.001
The dependent variable is loge leptin. The model r
2 is 0.764 for men and 0.620 for women. SE is the standard error for the regression
coefficient.
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IAF in humans (42). Low plasma levels of adiponectin
(43) have been associated with a state of insulin resis-
tance in animal models (44) and in humans (43); in the
animals, insulin resistance could be reversed by adi-
ponectin infusion (44). Recently, another adipocyte-
derived peptide, resistin, has been suggested to induce
insulin resistance (45), but this was not confirmed in
other rodent (46) and human (47) studies.
In addition to its role in glucose homeostasis, insulin
acts as an adiposity signal in the brain, leading to a
reduction in food intake (48). Another important signal
of body adiposity and recent energy balance that is
delivered to the central nervous system and limits food
intake is circulating leptin (49). The relationship be-
tween body fat mass and leptin concentrations is well
established (16,20). The larger SCF compartment has
been implicated as the determinant of leptin levels (50),
and this concept is supported by in vitro studies show-
ing greater leptin secretion (51) and leptin gene expres-
sion (52) by subcutaneous adipocytes than by intra-
abdominal adipocytes. However, others have found that
leptin levels correlate better with the size of the IAF
depot than with SCF in men (53). The latter finding is at
variance with our finding that SCF is the major predictor
of leptinemia, explaining 66% of its variance in men and
54% in women. In addition to the correlation with fat,
leptin secretion can be regulated by insulin via insulin’s
effect to stimulate glucose metabolism in adipocytes
(54), and, therefore, insulin sensitivity could be a deter-
minant of leptinemia (19). Some studies have shown
that this association disappeared after correction for
body fat mass (20,55), but others suggested it was an
independent determinant (56,57). The LIR subjects in
our study were indeed hyperleptinemic compared with
the LIS group, but their increased central adiposity
made it difficult to simply attribute this to their insulin
resistance. The fact that the difference in leptin levels
disappeared when a subgroup of LIS and LIR subjects
were matched for SCF illustrates the confounding effect
of body fat on this association. However, whereas the
effects of insulin sensitivity and fasting insulin concen-
trations on fasting leptin levels appear to be minimal,
this study did not address the relationship between
acute changes in insulin and leptin concentrations.
Because circulating leptin levels are not constant
throughout the day but exhibit a diurnal pattern that is
dependent on the state of energy balance (58), it is
possible that in the nonfasting state, leptin levels may be
determined in part by insulin action.
Our observation that fasting insulin and leptin levels
are elevated in obesity is in keeping with the findings of
Schwartz et al. (55), who found that insulin sensitivity
contributes to the association between body adiposity
and plasma levels of insulin but not leptin. The fact that
these signals of energy balance are elevated in obesity
also supports the concept of insulin and leptin resis-
tance in the central nervous system (59). Our finding
that IAF determines insulin sensitivity while the SCF
compartment correlates with plasma leptin levels sug-
gests that these depots may result in a difference in the
relative signaling to the central nervous system and
suggests that, whereas insulin and leptin may both be
important adiposity signals, their respective roles in
body weight regulation may be different. Future re-
search will help clarify whether a common mechanism
leads to this impaired central leptin and insulin signal-
ing and whether it shares similarities with the mecha-
nisms resulting in peripheral insulin resistance.
In conclusion, we have shown that accumulation of IAF
correlates best with insulin resistance and increased insu-
lin levels and that SCF deposition is better associated with
leptin levels in both genders. The concurrent increase in
these metabolically distinct fat compartments appears to
be the main explanation for the relationship between
elevated leptin and insulin levels. Whereas increases in the
two fat depots and in the respective adiposity signals are
well recognized in obese individuals, the present study
clearly demonstrates that the same phenomena can occur
in lean subjects.
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